Rhabdomyosarcoma (RMS) is the most common malignant tumor of the orbit in children, but it is rarely present at birth. We report a large congenital orbital RMS with intracranial extension in a newborn baby. A newborn baby girl was referred to our hospital due to severe right-eye exophthalmia. Imaging studies showed an orbital mass with intracranial extension. Treatment was started with a course of neoadjuvant chemotherapy followed by right orbital exenteration and intracranial resection of the tumor. Histologic examination of the mass showed undifferentiated malignant small-cell tumor. Immunohistochemical study proved it to be RMS. The patient was categorized as intermediate-risk RMS and chemotherapy was continued accordingly with VAC regimen. In spite of treatment, the infant developed intracranial recurrence at the age of 6 months and died 1 month later. Congenital orbital RMS has a poor prognosis. Reconstruction surgery should be deferred due to high rate of recurrence and low chance of survival. A multidisciplinary approach might increase the survival of these patients.

Keywords:
Rhabdomyosarcoma, Orbit, Congenital tumor, Exenteration
1.
Rao AA, Naheedy JH, Chen JY, Robbins SL, Ramkumar HL: A clinical update and radiologic review of pediatric orbital and ocular tumors. J Oncol 2013;2013:975908.
2.
Huh W, Mahajan A: Ophthalmic oncology. In: Esmaeli B (ed): Ophthalmic Oncology. Boston, Springer, 2011, pp 61-67.
3.
Arndt CAS, Stoner JA, Hawkins DS, et al: Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: Children's Oncology Group study. J Clin Oncol 2009;27:5182-5188.
4.
Singh AD, Traboulsi EI, Reid J, et al: Orbital cyst: prenatal diagnosis. Ophthalmology 2009;116:2042-2042.e2.
5.
Kikuchi K, Rubin BP, Keller C: Developmental origins of fusion-negative rhabdomyosarcomas. Curr Top Dev Biol 2011;96:33-56.
6.
Chen B, Perry JD. Rhabdomyosarcoma. In: Singh AD (ed): Clinical Ophthalmic Oncology. Philadelphia, Saunders Elsevier, 2007, pp 581-585.
7.
Oberlin O, Rey A, Anderson J, et al: Treatment of orbital rhabdomyosarcoma: survival and late effects of treatment - results of an international workshop. J Clin Oncol 2001;19:197-204.
8.
Rodary C , Gehan EA, Flamant F, et al: Prognostic factors in 951 nonmetastatic rhabdomyosarcoma in children: a report from the International Rhabdomyosarcoma Workshop. Med Pediatr Oncol 1991;19:89-95.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.